BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22094953)

  • 1. Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients.
    Sam WJ; Chamberlain CE; Lee SJ; Goldstein JA; Hale DA; Mannon RB; Kirk AD; Hon YY
    Transplantation; 2011 Dec; 92(12):1342-7. PubMed ID: 22094953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.
    Sam WJ; Chamberlain CE; Lee SJ; Goldstein JA; Hale DA; Mannon RB; Kirk AD; Hon YY
    Transplantation; 2012 Nov; 94(9):971-7. PubMed ID: 23073467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.
    Miao LY; Huang CR; Hou JQ; Qian MY
    Biopharm Drug Dispos; 2008 Jan; 29(1):1-5. PubMed ID: 17941052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients.
    Lee J; Huang H; Chen Y; Lu X
    Biopharm Drug Dispos; 2014 Apr; 35(3):164-72. PubMed ID: 24285256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.
    Rahsaz M; Azarpira N; Nikeghbalian S; Aghdaie MH; Geramizadeh B; Moini M; Banihashemi M; Darai M; Malekpour Z; Malekhosseini SA
    Exp Clin Transplant; 2012 Feb; 10(1):24-9. PubMed ID: 22309416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.
    Rodríguez-Jiménez C; García-Saiz M; Pérez-Tamajón L; Salido E; Torres A
    Drug Metab Pers Ther; 2017 Mar; 32(1):49-58. PubMed ID: 28245187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.
    Alatorre-Moreno EV; Saldaña-Cruz AM; Pérez-Guerrero EE; Morán-Moguel MC; Contreras-Haro B; López-de La Mora DA; Dávalos-Rodríguez IP; Marín-Medina A; Rivera-Cameras A; Balderas-Peña LA; Gómez-Ramos JJ; Cortés-Sanabria L; Salazar-Páramo M
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
    Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Vizzini G; Salis P; Caccamo C; Bertani T; Palazzo U; Polidori P; Gridelli B; D'Alessandro N
    Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients.
    Li Y; Yan L; Shi Y; Bai Y; Tang J; Wang L
    Springerplus; 2015; 4():637. PubMed ID: 26543771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.
    Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Biondi F; Sanguedolce R; Vizzini G; Palazzo U; Polidori P; Triolo F; Gridelli B; D'Alessandro N
    Ann Transplant; 2009; 14(1):23-31. PubMed ID: 19289993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
    Mourad M; Mourad G; Wallemacq P; Garrigue V; Van Bellingen C; Van Kerckhove V; De Meyer M; Malaise J; Eddour DC; Lison D; Squifflet JP; Haufroid V
    Transplantation; 2005 Oct; 80(7):977-84. PubMed ID: 16249748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
    Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
    Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
    Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
    Meng XG; Guo CX; Feng GQ; Zhao YC; Zhou BT; Han JL; Chen X; Shi Y; Shi HY; Yin JY; Peng XD; Pei Q; Zhang W; Wang G; He M; Liu M; Yang JK; Zhou HH
    Acta Pharmacol Sin; 2012 Dec; 33(12):1563-70. PubMed ID: 23085740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.
    Zhang X; Wang Z; Fan J; Liu G; Peng Z
    Eur J Clin Pharmacol; 2011 Aug; 67(8):803-13. PubMed ID: 21359536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy.
    Anglicheau D; Le Corre D; Lechaton S; Laurent-Puig P; Kreis H; Beaune P; Legendre C; Thervet E
    Am J Transplant; 2005 Mar; 5(3):595-603. PubMed ID: 15707415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.